An Open-Label, Multi-Cohort, Multi-Center Phase Ib/II Study to Evaluate the Safety and Efficacy of GB268 Monotherapy or Combination Therapy in Patients With Locally Advanced or Metastatic Breast Cancer (ChiCTR) - Oct 16, 2026 - P1/2 | N=270 | Not yet recruiting | Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR
|